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Patent and New Drug Protection and Innovation Promotion Policy 
 
 
1.  Patent Protection in Chinese Pharmaceuticals 
 
1.1. Historical Development of the Patent System 
 
The pharmaceutical industry is considered a special and important 
high-technology industry: investment into exploring new drugs is huge, the risks 
are high, and the investment period is long. Every new chemical entity require an 
expenditure of US$0.8-1 billion on average. It can take 10 years or more from 
discovery of the new drug to it finally being listed on the market. Recently, the 
number of new drugs listed on the global market has been decreasing drastically. 
Compared to other industries, it is becoming more difficult to see good results 
from research and development in terms of the number of new products. However, 
once a product has been successfully developed, not only can it contribute to 
humanity’s struggle with disease, protecting people’s health and lives, but it also 
provides massive profits to the innovators: the research institutes, pharmaceutical 
firms and distributors who invested in the project. This huge profit is guaranteed 
because of the market exclusivity afforded by intellectual property protection. 
Thus, the development of new drugs depends far more on intellectual property 
rights protection than in other industries. This heavy dependency of intellectual 
property protection is also indicated by the fact that drug patent applications 
consistently rank within the top three patent applications of any industry in China. 
On the other hand, drug applications have a bearing on the national health, and so 
the intellectual property protection system has to consider its impact on the 
public health. 
 
1.1.1 Revisions of Patent Law 
 
(1) In the Patent Law enacted on 1st April, 1985, the 25th clause clearly stated 
that a “patent will not be provided for a drug or new chemical entity.” In other 
words, the Patent Law did not give patent protection to drugs and chemical 
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entities themselves, but only to the process and methods used. In legislation, the 
weak innovation capacity of pharmaceutical firms in China because of its 
position as a developing economy is taken into greater consideration. If more 
rigorous intellectual property protection was taken, it was expected that this 
might damage the future development of China’s pharmaceutical industry. In 
order to affect the industry, sanctions on drug patent protection were then 
introduced. 
 
(2) 7 years after the introduction of first version, the Patent Law was revised on 
1st January, 1993. The revised Patent Law added protection towards drugs and 
new chemical entities, and extended the scope of protection to include products 
that were produced by a patented process, in order to keep the Chinese economic 
system consistent with international customs and in particular to revive China’s 
membership in the World Trade Organization. This was also consistent with the 
China’s Reform and Opening Policy. 
  
(3) Revisions in 2000 confirmed the 1993 Patent Law, clearly providing all drugs 
in China with patent protection. 
 
1.1.2 Objects of Patent Protection and Conditions 
 
Drug patents consist of the innovation itself, the drug’s practical use and the 
product’s appearance and design. The subject of the protection is the discovery of 
a new chemical entity, namely innovation; the new form and compound of drugs; 
and any new and revised process. Of these, the most important conditions to 
provide patent protection are novelty, creativity and practicality. “Novelty” 
shows that a similar drug has not been published in domestic or foreign 
publications prior to the patent application, nor have they yet been used either in 
public or announced in any other form, nor has patent administration been 
applied for or publicized by other persons. “Creativity” shows that the new drug 
has prominently substantial features and advanced progress, compared to the 
technology that existed before its application. “Practicality” indicates that the 
innovated drug should actually be able to be manufactured and utilized, and that 
it generates a positive effect. Likewise, the patent protection on a drug or process 
is provided with the newest in the world and the products of innovative effort. In 
terms of practicality, the patent only requires that the drug or the process is 
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applicable in industrialization, or the prospect of industrialization. Application in 
industrialization indicates that not only is the drug or new process capable of 
curing a disease, but also that is has been rigorously inspected regarding toxicity 
and/or safety. 
 
1.1.3. Time Period and Instruments of Patent Protection 
 
The Patent law clearly provides that an innovation patent is protected for 20 
years since the date of application. Practically speaking, those 20 years are 
classified in 3 stages, and the protection is strengthened step-by-step: as China’s 
patent system employs the principle of “publishing earlier, and investigating 
slowly,” during the period that a drug patent is applied for but has not yet been 
publicized, it is impossible for the other parties to know the details of any 
innovation, and thus cannot violate the patent as much. If an identical drug was 
innovated during this period, the innovator could not claim any compensation, 
because the patent protection would not yet have gone into effect, and the 
competition could neither apply a patent nor destroy the novelty inherent to this 
innovation. Therefore, this transitional period can be regarded as a period of 
“mutual non-intervention.” In the second period, when patent has been applied 
for but not yet approved, the general public is able to know detailed contents of 
the particular innovation. Thus, if another party were to utilize the same 
innovation, he would have to make payment to the innovator for the appropriate 
costs. This can be regarded as the period of “transitory protection.” During the 
third period, when the patent has been approved, no institution or individual can 
utilize the patent to manufacture for sale, use, license the sale, sell, import the 
patented products, or utilize the patented process, nr can they use, sell, license 
the sale, or import products that directly rely on that particular patent. During 
this period, if somebody utilizes the patent without the approval of the patent 
holder, the patent holder or another stakeholder can file a complaint with the 
courts, or ask that the patent administration require the violator stop that 
violation and to make compensation. This is the period of “complete protection.” 
 
According to clauses in the Patent Law, only one patent is approved for each one 
innovation. Because of this provision, patent protection provides exclusive 
marketability. In other words, each patent protects only one new drug. This 
exclusivity can lead to monopolized profit from the market, including production, 
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sales, use and importation of the new drug. The profit is huge. 
  
1.1.4. Routes for Legal Relief  
 
The Patent Law states that when the Intellectual Property Department under the 
State Council rejects a patent application, the applicant can ask the patent review 
committee for a re-investigation within a given period. After the publication date 
of patent announcement by the State Council, any institution or individual who 
finds it irrational, can request that the review committee make the patent invalid. 
In the case where the applicant objects to the decision of the review committee, 
he can file a lawsuit to the court within a given period.  
 
 
1.2  Data: Patents and Pharmaceutical Firms’ Development 
 
1.2.1 Overall Situation 
 
The number of patent applications and approvals indicates the growth of the 
number of patents and also indicates levels of innovation capacity and 
sustainability. We have analyzed the descriptive data of patent applications for 
new drugs and biotechnology in China for the 21 years between 1985 and 2005. 
Figure 1 shows the historical development of number of patent applications and 
approvals. Here we can see a trend of steady growth. We must note at this point 
that as there exists a time lag between a patent’s application and publication - 18 
months on average – the figures representing the number of patents for the final 2 
years (2004 and 2005) are incomplete. A decrease is indicated because of this 
technicality, but it does not reflect the actual development. 
 
 
 
Figure 1: Number of Applied Patents 
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1.2.2: Geographical Distribution 
 
(1) Distribution by Country 
In terms of the number of patent applications by foreign institutions between 
1985 and 2005, the US remains consistently at the top, with Japan, Germany, 
Switzerland, and the UK following.  
 
Figure 2: Number of Patent Applications by Country 
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(2) Distribution by Region 
The number of patent applications indicates that a disparity apparently exists 
between different regions. Beijing, Shanghai, Guangdong, Shandong, Henan, 
Hunan, Hebei, Jiangsu, Tianjin, and Zhejiang rank as the Top 10, however the 
number of applications from Xinjiang and Tibet are very few. This shows that 
patent applications are concentrated in China’s developed areas: the 
Beijing-Tianjin area and the Yangzijiang River area.  
 
Figure 3: Number of Patent Applications by Region 
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(1
There are three categories of IPC classification
biotechnology: the raw material drug manufacturing patent, the drug formulation 
patent, and the biotechnology patent. Approved patents for raw material drugs 
from 1985 to 2005 numbered 12,401, drug formulation patents numbered 53,383, 
and biotechnology patents numbered 29,021 - making 94,805 in total. 
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ong the three 
p
categories: the biotechnology category has 3,652 items and the organic chemistry 
category has 49,731. This explains that innovation in drug formulation has to 
date depended heavily on traditional chemistry methods. However, along with the 
development of biotechnology and the increase in society’s attention to it, 
biotechnological drug formulation has huge room for further development. 
 
Of the 94,805 drug patents, patents on natural extract drugs count for 2
w
patents, domestic institutions applied for 21,709 – a 98% share - and foreign 
institutions applied for only 515 (shown in Figure 5). This phenomenon indicates 
that China has an apparent advantage in the natural extract drug category, and 
this is the area in which China has most independent innovation capacity and is 
the easiest field in which to acquire intellectual property.     
 
Figure 5: Patent Applications for Natural Extract Drugs 
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 shown as follows: patent applications for anti-tumor drugs numbered 13,050, 
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(3) Patent Classification by Diagnosis Classification 
Data on the number of patents by diagnosis classificatio 1985 and 2005 
is
cardiovascular drugs accounted for 10,795, anti-biotic 
drugs for 7,439, skeletal disease drugs for 6,490, skin disease drugs for 6,170, 
central nervous system drugs for 5,786, respiratory organ drugs for 4,586 
reproductive organs drugs for 4,351 and metabolic drugs for 3,715. The above 
data indicates that patent applications concentrated on drugs for high frequency 
diseases. In particular anti-tumor and cardiovascular drugs are the core of new 
drugs development. 
 
Figure 6: Number of Patents for Drugs by Diagnosis Classification 
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(3) Analysis by Patent Classification 
Among the 94,805 patents, there were 93,051 new product patents and 1,754 
practical new forms. This indicates that the innovation of new product patents is 
dominant. 
 
Figure 7: Number of Patents by Patent Type 
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1.2.4 Analysis of Competitiveness by Institutions 
 
(1) Distribution of Patent Application Types 
In order to analyze competitiveness by institutions, we must look at the number 
of patent applications for new drugs and biotechnology by research institutions, 
universities, corporations, hospitals, individuals and other groups between 1985 
and 2005. In twenty years, 94,805 patents were applied for in total: of these, 
corporations accounted for 43.42%, individuals and others for 32.9%, 
universities for 13%, research institutes for 9.4 % and hospitals for 1.3%. Figure 
8 presents this data. Corporations and individuals are the dominant figures. 
 
Figure 8: Number of Patent Applications by Applicant Type 
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(2) Patent Applications by Foreign Pharmaceuticals in China  
Here we look at the patent applications for drugs and biotechnology by the top 10 
pharmaceuticals in the world (1985-2005). Pfizer had 850 applications, Johnson 
and Johnson 35, Graxo Smith Kline 211, Novartis 35, Roche 16, Merk 427, Abbott 
0, Astrazenega 58, Sanofi-Aventis 132, and Wyeth 348. 
 
Figure 9: Global Top 10 Pharmaceuticals’ Patent Applications in China 
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1.3. Current Situation and Future Analysis 
 
Hereafter, we will relate the innovation capacity of the pharmaceutical industry 
in China by following a SWOT analysis. SWOT represents Strength, Weakness, 
Opportunity and Threat. 
 
1.3.1. Strengths 
 
(1) Academic Support for the Development of Pharmaceutical Patents 
A scientific project called the “863 Plan” enacted by the State focuses on the 
pharmaceutical and drug industries. As we have already seen above, the number 
of patent applications for modern biotechnological products is gradually 
increasing, and the modern biotechnology industry is also developing rapidly. 
More than 20 biotechnology science parks are operating in China, and each of 
them generates a supporting industry: these supporting industries may contribute 
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to the progress of the research into, and industrialization of, its products. Thanks 
to support from the 863 Plan and other development plans, scientists in China 
were able to organize inter-disciplinary joint research, and to accumulate 
abundant experience. 
 
(2) Rapid Progress in the Patent Protection Systems 
The number of applications for patents from the biological and new 
pharmaceutical industry reached 13,222 in 2003, a 30.61% growth compared to 
the previous year.  It has increased to 25.33 times that of 1985. 
 
(3) Rapid Growth of Biological and Natural Extract Patents 
As we have seen in the data analysis above, patent applications based on 
biotechnology have grown aggressively since 1999. The potential for growth in 
this field is widely perceived and encouraging huge input. 
 
On the other hand, domestic institutions are responsible for 98% of natural drug 
patents. This implies a potential for innovation in natural drugs, and a high 
possibility of Chinese institutions being able to acquire intellectual property 
rights. 
 
1.3.2 Weaknesses 
 
(1) Poor Outcomes and Poor Input in Medical Biotechnology Research  
As we have seen in the data on patent applications, its growth is currently very 
high. This is due to the fact that the starting base was small: the number of patent 
applications in the field of medical biology from 1985 to 2005 was only around 
90 thousands, whereas applications in the US reached around 20 million. Input on 
medical biotechnology research was very poor, only one 500th of China’s foreign 
counterparts. Inputs on basic research would have been very small and, 
simultaneously, because of poor promotion, input by the commercial base was 
also particularly small, leading to slow development in this field. 
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(2) The Level of Technology in Drug Patents is Low 
Currently, the level of technology drug patents is not high in general, and the 
number of patent applications for new chemical entities is very small. Patents for 
the form of drugs were primarily for traditional drug forms, and patents for 
innovative forms like slow or controlled emission were few. Although the 
number of patent applications for drugs made from plants by domestic 
institutions is large, the patent is limited to new combinations of drugs, which is 
far below the Modern Traditional Chinese drug requirement. In the area of 
biological technology, patent novelty is limited to traditional enzymes or 
fermentation in most cases, and in very few cases were patent applications made 
for genetic technology. 
 
(3) Weak Perception of Patent Protection by Scientists 
Although the Patent Law has been enacted for more than 20 years, and although 
systematic promotional activities have been conducted nationwide, they were 
limited to a few management positions, and most of staff working in the research 
and development departments lack any legal knowledge of patent protection and 
thus did not apply for patent protection immediately after the products were 
developed. As a result, the phenomenon referred to as “too much respect for the 
outcome, too much neglect of patents” has very prevalent in the pharmaceutical 
industry. For example, the two-step fermentation method of Vitamin C is an 
advanced technology at the international level, but the innovator did not apply for 
patent, but only published a paper. A foreign firm prepared US$5 million to buy 
out this technology along with the equipment, but the firm only paid several 
hundred thousand dollars for the paper once they knew that the innovator had not 
applied for a patent. They then produced generic versions in their home country. 
After several years, Vitamin C produced with this technology abroad was 
unloaded and it seriously damaged the export price of Vitamin C from China, 
created a crisis for firms who produced Vitamin C in this country. 
    
(4) Weak Innovation Capacity of Pharmaceutical Firms 
In China, main innovators in pharmaceuticals have been the research institutes 
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and universities; the firms themselves have been weak at innovation. This is in 
contrast to situation abroad, where it is the firms that are the innovators of new 
drugs. 
 
1.3.3 Opportunities 
 
(1) WTO Entry  
Re-entry into the World Trade Organization (WTO) has provided domestic 
pharmaceutical firms with a good opportunity for international alliances or 
acceptance of foreign investment. This is a strong advantage for upgrading the 
pharmaceutical industry’s research capability. International cooperation and 
alliance have seen progress after entry into WTO: both joint research and 
development and also product sharing of development results. International 
cooperation and alliances based on mutual advantages have seen a good response 
for high-risk and high-input projects like pharmaceutical development. In 
addition, re-entry into the WTO removed the obstacles to the entry of foreign 
firms and institutions into the Chinese market and their subsequent huge 
investments in research and development. This is good news for the Chinese 
pharmaceutical industry, which was suffering from shortages of funds. 
 
(2) Drug Demand will Grow with Upgraded Living Standards 
Currently, the consumption of drugs per capita in China is far lower than the 
international levels. However, following the natural increase and aging of the 
population, and the growth of the economy, the pharmaceutical industry has been 
growing rapidly.  During the tenth Five Year Plan, a new focus on the 
development of the pharmaceutical industry was announced as follows: 1) Steps 
to induce internal development in order to upgrade innovation capacity and 
quality. 2) Investment should be concentrated on upgrading innovation and 
quality, and economies of scale should no longer be pursued. 3) The new “hot 
spots” of development will be traditional Chinese medicine, biotechnology 
development, and chemical raw materials. High growth of the macro economy 
and rationalization of administrative management will provide better 
 45
opportunities for development. 
 
1.3.4. Threats 
 
(1) Increase in Patent Applications by Foreign Pharmaceuticals 
The data above shows not only the increase in patent applications by domestic 
institutions, but also shows that foreign institutions similarly increased the 
number of patent applications in China. The purpose of patent application is, of 
course, to monopolize the market for a particular drug category or research in 
China. China, as a huge market with a population of 1.3 billion, is a big cake that 
is tempting foreign pharmaceuticals to apply for patents. The US firms are a good 
example of this. 
 
(2) Outflow of Human Resources and Output in Pharmaceutical Industry 
In the data analysis we found that Chinese individuals are the primary innovators 
in many patents, however the patent applications come from foreign institutions. 
This implies that this is the outcome of Chinese scientists flowing abroad and 
subsequently being utilized by foreign institutions. Although the amount of 
Chinese innovators’ output might be a very small figure compared to the world’s 
innovation and patents, nevertheless this “small” number of innovations is not so 
small for Chinese scientists. This indicates that though although there are human 
resources in China, they are flowing out. 
 
As a whole, though we have several problems in China that are now threatening 
the country’s development, we do not have to belittle ourselves as we have 
several advantages that could help us maintain a leading status in the market and 
also provide us with a huge opportunity. Thus, what we should do is to calmly 
analyze and set out a development strategy and response in order to respond to 
any challenge by those who are stronger.  
 
 
1.4. Strategy for the Drug Patent Protection System in China 
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 China’s pharmaceutical industry is facing all at once an opportunity and a 
challenge, difficulties and hopes. A development strategy should be designed to 
strengthen the industry’s strong points, and make the weak points strong, in order 
to achieve fast growth.  
 
It is necessary to improve the perception of the importance of patent protection, 
in order to complete related policies and administrative management. (1) In order 
to strengthen intellectual property protection and management for all the 
processes of pharmaceutical supply, from research and development to 
production to sales, it is necessary to utilize the protection and information 
functions of an intellectual property rights protection system. (2) In order to 
improve innovation and industrial development in the pharmaceutical industry, it 
is really necessary to protect pharmaceutical firms, consumer welfare and to 
improve international competitiveness. 
 
(1) Complete the Intellectual Property Protection System for 
Pharmaceuticals 
As a member of the WTO, China should study and comply fully with the TRIPS 
agreement（Agreement on Trade-Related Aspects of Intellectual Property Rights）
and any other related rules. Only under the TRIPS agreement and related rules 
can China resolve international conflicts over intellectual property rights. 
 
In order to respond to intensive competition in both the domestic and export 
markets, new trends in the treatment of intellectual property rights in 
international markets should be reviewed, and any policies and administrative 
management by the central and local governments should comply with these. 
 
In order to analyze, judge and set out a patent protection criteria that would 
prompt entities to exercise China’s comparative advantages, as well as the 
administrative management system that would prompt the State to grasp key 
technology, it is necessary to perform an in-depth study into a standard that 
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would protect new technology in the pharmaceutical industry, as well considering 
the different sources of competitiveness in both domestic and foreign firms. In 
addition, any intellectual property protection policy should be consistent with the 
current situation within China, based on an analysis and forecast of the 
development trends of pharmaceutical intellectual property rights. 
 
(2) The Government Should Strengthen Policy Support 
The government should support patent protection in the pharmaceutical industry 
by intervening through its technology policy, industrial policy, tax and monetary 
policy, human resources, imports and exports, investment and procurement, and 
international co-operation. An example would be to allow medical reform to be 
consistent with the innovation capacity, or offering favorable treatment of newly 
innovated products on the basic drug list.   
 
In addition, a preferential universal tax policy toward any input on research and 
development is also necessary. Compared to in a developed economy, China’s 
current tax system, a production-based value-added tax, is unfavorable towards 
any input on research and development. The tax system needs to be revised: first 
of all, to transform it into consumption-based value-added tax, and at the same 
time reducing the tax rate for input to research and development by reducing the 
tax base and enlarging the tax reduction target. Secondly, the system should be 
revised to reduce the income tax for research and development input and to 
redeem it immediately when the firm has actually implemented that input for 
research and development. Thirdly, the system needs to be revised in order to 
universally redeem the value-added tax on any research development input, and 
to transform the favorable tax redemption policy from being direct towards a 
limited group of firms to being the universal policy. In that way, we can 
implement a tax redemption policy towards the research and development of all 
pharmaceutical firms. 
 
(3) Rationalization of Procedures 
The application and maintenance of patent are form of legal action, and the 
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patent administration department should manage whole process consistently. 
Research institutions and universities should be established to deal with patent 
issues and at the same time a group of capable patent agents should be 
encouraged. By means of these, we can change the current management level, 
which suffers from poor content and a lack of efficiency. Patent management will 
only work effectively when patent agents that are highly capable and extremely 
efficient, and who have received expert training, appear, and when 
rationally-operated administrative management and regulations are established. 
 
Patent investigation standards can act as a weather vane, and at the same time 
they have some leverage. Novelty is a hard index of the patent investigation, and 
creativity is a flexible index. In order to protect traditional Chinese medicine, a 
further study on the relationship between creativity and judgment of patent rights 
violation is necessary so as to set up a standard for creativity in traditional 
Chinese medicine. It would be more idealistic if quantification were feasible, and 
it was possible to control the investigation on creativity based on a quantified 
index. 
 
(4) Firms Should be Agents of New Drug Innovation 
Currently, research institutes, sponsored by the government, or the universities 
are the main undertakers of research and development. New drugs are listed 
through: (1) cooperative projects by research institutes and pharmaceuticals 
firms: the firm will finance the project, while the research institute conducts 
research, and they then apply the new drug together. This is a very common form 
of cooperation. (2) Research institutes complete the research into a new drug and 
applied the “New Drug Documents,” then they transfer them to pharmaceutical 
production firms. Research institute will invest this technology-transfer fee in 
future new research. (3) A research institute will not only complete the 
development work, but will also help the firm with the production process, and 
will receive fee based on a ratio to the sales. the research institute will use this to 
fund another new project. 
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In the rest of the world, large international firms shoulder the responsibility for  
new drug developments. These big pharmaceuticals, like Pfizer or Novartis, 
inject around 15-20 of sales or more of sales into research and development. 
Huge investments, excellent scientists, fine precision machineries, and a rational 
innovation mechanism make these pharmaceutical firms able to “produce one 
generation, develop one generation, research one generation, and imagine one 
generation” a successive list new drugs. Merck & Co. employs almost 5,000 
scientists conducting research and development, making distributions in 7 
countries and 8 research laboratories. Because of the size of this investment, the 
corporation has been able to maintain its current rank as the top pharmaceutical 
company in the world. 
 
Currently, universities and research institutes carry out research and development 
into new drugs in China. Pharmaceutical firms often do not have their own 
independent research and development departments, instead relying fully on 
buying in or transferring the outputs of research institutes for new drug listings. 
However, as research institutes are far from market, the firms often find it 
difficult to purchase ideal development results that are appropriate to their 
market. Being faced with intensified international competition, the firms should 
instead build up their own research and development teams. In the future, the 
government should input basic research, and firms should then carry on applied 
development research.  Currently, the firms are too small, and there is a 
historical division among firms, academics and research institutes. These factors 
become obstacles to the firms’ goal of being true innovators. As a result, when 
the government requires firm to develop new drugs, it is not enough to simply 
search for developed generics of market-bestsellers, but instead firms must first 
be allowed to build up a long-term development plan that includes their own 
development. The firms can become modern pharmaceutical firms that integrate 
the processes of research, production and trading, as well as such entities as 
manufacturers, academics and research institutions, by means of corporate 
alliances and mergers and acquisitions. 
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(5) Utilize the Advantages of Traditional Chinese Medicine 
In the field of plant drugs, the US, Japan and Germany lead the world. These 
three countries share more than one fifth of the world’s patents. In particular, in 
terms of number of patent applications for plant drugs, Japan leads both the US 
and Germany – this indicates that cultural and natural plant resources are 
favorable to the research and development of drugs. 
 
Artemisinin (Qinghaosu) is a very rare drug that a Chinese company has 
independently researched and developed based on science funding by the 
government in the 1970s, and held a patent in for 15 years since 1987. That 
patent expired in 2003 However, a foreign competitor, Novartis, succeeded in 
producing generics based on scientific literature, and then applied for a new 
patent for a new combination. However, because that company has a leading 
position in the market, by becoming leading supplier for the WHO, their patent 
protection can be extended in their own country. (See also the “Case-study on 
Fosun Pharmaceuticals” in Chapter 5).  A second case is that of the “Jin Long 
Capsules,” which caused a US$2 billion loss for Beijing Jiansheng 
Pharmaceuticals. The company claims that Novartis plagiarized their   
development achievement: a new prescription method for the anti-cancer drug 
arteminisinin. Novartis utilized their research results, developed the anti-cancer 
pharmaceutical “Gleevec,” and already received permission for clinical trial from 
the US’ Food and Drug Administration (FDA).  If Beijing Jiansheng 
Pharmaceutical had a stronger perception of intellectual property and had made 
an application for the new drug at the FDA in the US, they could have seized a 
leading position in the market.  These two cases both act as a powerful warning 
to traditional Chinese manufacturers: due to poor intellectual property 
management, Chinese traditional medicine manufacturers have to pay patent fees 
for their own traditional prescriptions.  
 
Traditional Chinese medicine is a specialized field of medicine. Chinese 
companies have advantages in research and development in this field: China 
already has abundant resources for this kind of medicine - not only 12,807 
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natural resources, but also prescriptions accumulated over several thousand years, 
which contains rich scientific information. This is an advantage that only China 
holds in the world. 
 
Intellectual property protection is an internationalized legal system to protect 
intellectual property rights. It is critical for the legal system to protect natural 
resources in China and to support competitiveness of Chinese drugs in the 
international market. Development of new technology in traditional Chinese 
medicine relies not only on scientists in this field, but also institutional support 
from the government. 
 
After its re-entry into the WTO, traditional Chinese medicine, particularly 
formed TCM and health food, are those fields that could most expect 
international competition. Apply for international patents in TCM, formed TCM, 
and TCM health food would work as a first step towards building international 
advantages for the whole Chinese pharmaceutical industry. 
 
The pharmaceutical industry’s contribution towards intellectual property rights is 
huge. Faced with intensive competition and challenges, China must be 
sufficiently aware of the lag in intellectual property protection in the country, and 
should be more conscious of property protection. To summarize, in order to 
develop and acquire international competitiveness in the pharmaceutical industry, 
China must promote its intellectual property rights. 
(CHEN Jing, CAO Jinyan and SHI Luwen) 
 
2.  New Drug Protection Policy  
 
2.1  Laws and Regulations and the Incentive Structure 
 
When the economic reform started in China, the first priority for the 
pharmaceutical industry was to secure a sufficient supply of pharmaceuticals to 
maintain the existing level of healthcare in the nation. In order to fulfill this 
target, government policy’s first priority was the production of generics policy: 
the first Drug Management Law, enacted in 1985, provided “new drug 
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protection” independent of patent protection. Any new pharmaceutical chemical 
entity could not be patented until the Patent Law was revised in1993. Even after 
new chemical entities in drugs were able to be patented, “new drug protection” 
provided “market exclusivity’ with the protected pharmaceutical firms, 
independent of “patent protection.”   
 
Under this scheme of new drug protection, market exclusivity was given to 
introduction of new technology, so to speak, but not to research and development 
into new chemical entities. This was a unique industrial policy for China, which 
contrasts with India. In India, patent protection for pharmaceuticals has been 
denied, as it is not inappropriate, ethically speaking, to allow a firm to 
monopolize on pharmaceutical production and the ensuing profits, as it matters of 
the life and death of the people. China accepted patent protection and, 
simultaneously, also provided market exclusivity to technology introduction by 
domestic firms, which remains consistent. 
 
Table 1 shows the development of new drug protection: from 1999 to 2002, 
market exclusivity given to a new chemical entity (class 1) was as long as 12 
years. This could be longer than patent protection on some occasions, as the 
patent protection period was counted from the date of application, not of product 
listing. Usually, the patent is applied for when research and development is 
underway, and it will take several years to list the new drug products after 
completing clinical tests. Thus, the protection period for new drugs could be 
longer than the patent protection. 
 
In 2002, “New Drug Protection” was replaced with the “New Drug Monitoring 
scheme.” Upon re-entry into the WTO, new drug protection became inconsistent 
with the idea of intellectual property protection systems under TRIPS. Because of 
these circumstances, the Act was revised to be consistent with international 
customs: first, market exclusivity was not provided manufacturers’ introduction 
of a new technology, but instead is provided when responsibility to monitor the 
safety and effectiveness of the drugs is undertaken in exchange for market 
exclusivity. Secondly, the definition of “new drugs” was changed from “those not 
produced in China” to “ those not listed in China.” The New Drug Monitoring 
Scheme was planned to monitor new drugs for safety and effectiveness, by 
providing market exclusivity to the supplier of that new drug. However, the 
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period of market exclusivity was reduced from 12 years to 5 years for the Class 1 
new chemical entities, and raw materials and active/intermediate were taken off 
the monitoring list (Table 2). Thirdly, data on new drugs, which was submitted by 
the drug’s developer, became legally protected, which it previously had not been. 
As a whole, property protection for pharmaceuticals was strengthened and 
become consistent with the current international standards. 
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Table 1: Market Exclusivity Under the New Drug and Patent Protections (Chemical Drugs) 
 
Classification 1985  
Drug Controlling 
Law 
1999  
“New Drug Registration 
Act” and “Notice on New 
Drug Protection and 
Technology Transfer”  
2002 
New drug protection in   
“Revised Drug Management 
Law,” “Drug Management 
Act” (Note 1) 
Patent Protection  
Class 1: new chemical entity that has not been 
listed anywhere in the world 8 years 12 years Transitory protection  5 year 
15 years (-1993) 
20 years 
(1993-) 
Class 2: Listed abroad, but not listed in the 
foreign pharmacopoeia, nor imported to 
China 
6 years 8 years 4 years None 
Class 3: New combination of registered drug 4 years 8 years 3 years None 
Class 4: Listed on the foreign 
pharmacopoeia, imported in China but not 
produced in China (not listed in China since 
2002) (Note 2) 
3 years 6 years 3 years None 
Class 5: New use of already registered drug 3 years 6 years 3 years None 
(Source) Related regulation and Deng and Kaitin [2004] 
(Note 1) On introduction of the “Revised Drug Management Law” and “Drug Management Act” in 2002, “new drug protection” was abolished, and the “new 
drug monitoring” period was introduced in 2002. The following transitional measures were taken: 1) drugs that passed clinical tests on 15th September 2002, 
were given market exclusivity for the period of “new drug protection” in the 1999 scheme. 2) Drugs that were applied for to the government, but had not 
passed a clinical test yet, nor sold in China, were given a “monitoring period” in the new 2002 scheme. (Note 2) The class 4 category is unique in China to set 
up for protecting domestic firms in securing a sufficient supply of pharmaceuticals. The 1999 Drug Application Act provided 8 types in this category: 
(1) Raw materials, Intermediate, and drugs listed on the foreign pharmacopoeia. 
(2) Raw materials and intermediate and/or drugs already imported in China (drugs that was manufactured by the raw materials or intermediate which was 
imported for research and development are categorized here.) 
(3) Any drug or its optical isomer whose synthesis method is already know and registered abroad. 
(4) Any drug that utilizes acid or alkali or replaces metal elements of a drug already sold in China, or holds a similar pharmacology mechanism. 
(5) Compound or change of drug formation of a drug that is listed in abroad. 
(6) Drug that is manufactured from imported raw materials. 
(7) Drug that changed drug formation. 
(8) Drug that changed use 
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Table 2: Monitoring Period in “Notice Related to Revised Drug Registration 
Act” 
 
Monitoring 
Period 
Classification 
5 years z Among drugs not listed in the world, drugs that contain 
(1) New chemical entities 
(2) New biological pharmaceuticals,  
(3) Optical isomers of an already known entity 
4 years z Among drugs not listed in the world, drugs that contain 
(4) Compound of a known entity where the amount of the effective entity is 
reduced but retains the same effectiveness 
(5) New compounds of a known entity 
(6) New delivery systems  
z Among drugs that were listed abroad, but not in China, drugs that   
(1) Are listed abroad in 2 years, or changed its drug formation 
3 years z Among drugs that were listed abroad, but not in China, drugs that  
(2) Are listed abroad more than 2 years ago, or changed its drugs formation 
(3) Contains new compound of known entity 
(4) Changed drug formation 
(5) Have new delivery systems 
z Drugs that utilize new salt* of known pharmaceuticals, with a similar 
pharmacological effect, as raw materials 
z Drugs that changed formation, but not delivery systems, with special 
technology (slow delivery system etc.) 
Out of 
monitoring 
z Among drugs not listed in the world, drugs that  
(7) Were listed in China, but had added a new therapy that was not approved 
globally 
z Among drugs that were listed abroad, but not in China, drugs that  
(7) Added a new therapy that was approved abroad 
z Drugs that changed the formation of drugs listed in China, but saw no 
change in use 
z Raw materials and active intermediates. 
(Source) State Food and Drug Administration, Notice on Revised Drug Registration Act, 23rd 
June, 2005 
(Note *) Salt is a material that is produced by an acid base reaction. 
 
 
2.2  Outcome of “the New Drug Protection” 
 
Criticism over inconsistencies in patent protection and the new drug protection was 
strong, and finally new drug protection was removed in 2002. The policy had the 
following outcomes: first, numerous Chinese firms invested in the industry, and started 
the production of drugs for 20 years and succeeded in meeting the basic needs of 
pharmaceuticals.  The first target set in the 1980s was fulfilled. Secondly, however, 
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“new drug” approval in China was separate from the outcome of actual research and 
development, as the policy designed to induce technological introduction was more or 
equally profitable to the actual research and development.   
 
Table 3 shows the number of “approved new drugs” in China and the US. The number 
of new drugs approved in China is extraordinary larger than the US, taking into account 
that these drugs were introduced as part of a program to catch up with world. In 
worldwide trends, the number of new drugs discovered is decreasing. One respondent in 
our interview said that it was the time for synthesis technology to reach its limit, and 
that a new technological breakthrough seems to be necessary for the pharmaceutical 
industry. 
 
Table 3: “New Drugs” Approved by Authorities in China and the US 
 
  2003 2004 2005  
China  Class 1 new drug 76 91 212 
 Actual # of new entities 11 24 17 
US FDA approved new chemical entities   3 
(Source) China: The industrial map of China Pharmaceuticals 2006-07, Social Sciences 
Academic Press. Caijing Magazine, 16th April, 2007, p.66. 
 
Table 4 demonstrates the development of a number of new chemical entities (Class 1 
new drugs). Here we can see that number of new drug approved increased explosively 
since 2000, when 17 Class 1 drugs were approved, though only 23 were approved 
between 1985 - 1999. This implies that explosive registration of new drugs might be 
related to the corruption of the ex Director of the SFDA, who was arrested in 2006.  
 
Table 4: New Chemical Entities Approved as Class 1 drugs between 1985-2000 
 
Developer of New 
Drug 1985-2000 Note 
Approved in 
2000 
Chinese 
Manufactures 26 
z Independently developed by 17 
Domestic Research Institutes: 
anti-malarial (6), anti-cancer (2), 
anti-platelet (1), anti-infective 
(2), anti-toxin (1), anti-AIDS (1), 
anti-allergin (1) anti-dizziness
6  
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(1), abortifacient (2) and 
cardio-protective (1)) 
z Developed by domestic research 
institutes based on the 
information provided in foreign 
publications at the outset of the 
research program. 
Foreign 
Manufactures 
(including joint 
ventures with 
domestic maker) 
12  10 
Outsourced 
manufacturing by 
domestic maker to 
foreign research and 
development firms 
2  １ 
Total 40  17 
(Source) Deng and Kaitin [2004] 
 
Thirdly, a large number of new drugs have provided huge room for Chinese 
pharmaceutical firms to enter and operate in the industry, which has brought about 
sufficient production capacity in the industry. However, as the new drug protection 
could be more profitable to research and development at a certain moment, the 
pharmaceutical firms are less interested in research and development, although this 
activity requires long periods and sensitive management to induce scientists’ inspiration 
and abilities. This could have induced the current reduction in investment in innovation 
that is greatly worrying the Chinese government. 
 
2.3  Relationship between Patent Protection and New Drug Protection  
 
This section covers the “new drug protection policy” in detail.  This is because new 
drug protection might open up patent protection, if it is provided without any 
connection to patent protection. Figure 10 defines the “market exclusivity protection 
period” by both patent and new drug protections. In accordance with global practices, 
patent protection will be provided from the date of a new drug’s application. Usually the 
patent is applied for during a stage of research, and it would take several years to list the 
products after completing the rest of the research work and clinical trials. If it takes 10 
years between application and listing, 10 years’ exclusive market protection remains for 
the patent. On the other hand, exclusive market protection based on new drug protection 
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is provided since the date of listing. If the period for new drug protection is long enough, 
it effectively provides a longer protection period than patent protection.    
 
Figure 10: Patent Protection and New Drug Protection 
(a) Patent Protection 
                      Protection Period 
                     15 years: 1987-1993  
 20 years: 1993-  
    
Application              Listing Date 
 
(b) New Drug Protection 
Protection Period (Class 1 New Drug) 
                       8 years: 1985- 1999 
                      12 years: 1999-2002 
                       5 years: 2002-  
 
      Listing Date 
(Source) Author 
 
This confusing situation seems to have actually occurred from 1999 to 2002, when the 
“Notice on New Drug Protection and Technology Transfer” was effective: the protection 
period of class 1 drug was as long as 12 years. Quite a few firms only applied for the 
new drug document, as its protection period was longer than the patent protection itself. 
Furthermore, as the new drug protection did not explicitly require patent application, 
generic manufacturers could apply for new drug protection by following the work of a 
published paper and any other publication written by the innovator. This effectively 
weakened patent protection. 
 
On the entry into WTO, the “Notice on New Drug Protection and Technology Transfer” 
was invalidated, and currently market exclusivity is provided based on the “Monitoring 
Period of New Drug’s Side Effects.” The longer protection for new drug provided in 
1999 to 2002 are now expiring, but its impact over the industry remains. 
(Mariko WATANABE) 
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3. Innovation Promotion Policies  
 
In the following subsections, we introduce several major factors that significantly affect 
the Chinese pharmaceutical industry’s innovative activities. Other than (1) policies 
directly encouraging innovation, (2) introduction of Drug Catalogues and (3) Price 
regulation policy substantially affect innovation incentives. We skip (2) and (3) as they 
are detailed in a separate section of this report: Drug Catalogues (Chapter 1: Demand) 
and Pricing Policy (Chapter 2: Price Setting Institutions).  
 
3.1. Innovation-Encouragement Policies 
 
There are a series of innovation-encouragement policies, which provide a great 
incentive for Chinese pharmaceutical firms to take up innovation activities. For example, 
the Chinese government has announced and implemented policies of 
revenue-encouragement, tax-incentives, direct financial aid, government purchasing, 
and increasing IPR protection, among others, to benefit the development of innovation 
in the pharmaceutical industry. Some of the detailed measures include: 
 
1. Increased direct investment in pharmaceutical science and technical innovation, 
in order to build a pharmaceutical innovative system that is market-oriented, 
consists of enterprises as a main body, and combines the industry, universities, 
and institutes together to innovate; 
2. Encouraging and supporting enterprises in setting up R&D centers by means of 
a series of favorable measures, such as tax credits or concessions, speeding up 
the depreciation of R&D facilities and equipments, etc; 
3. Establishing and improving certain public platforms (for example, the public 
technology support platform of the pharmaceutical industry, the industrialization 
support platform, the pioneering service platform and the environmental policy 
platform) to help firms reach their innovation objectives; 
4. Encouraging firms to provide effective and marketable innovative products by 
means of demand-encouragement, such as government purchasing; 
5. Patent protection for pharmaceuticals became law in China in 1993, which is 
greatly encouraging firms to carry out more and more innovative activities. 
(CHEN Xiaohong and XIANG Anbo) 
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